Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  de Bruyn, Marco ^a   Rybczynska, Anna A ^a   Wei, Yunwei ^a,b   Schwenkert, Michael ^c   Fey, Georg H ^c   Dierckx, Rudi A J O ^a   van Waarde, Aren ^a   Helfrich, Wijnand ^a   Bremer, Edwin ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Hospital of Harbin Medical University   (China)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE 1; HYBRID PROTEIN; MELANOMA CHONDROITIN SULFATE PROTEOGLYCAN ANTIBODY; MELANOMA CHONDROITIN SULFATE PROTEOGLYCAN ANTIBODY TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND HYBRID PROTEIN; PROTEOCHONDROITIN SULFATE; RIMCAZOLE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; PROTEOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ANCHORAGE; CELL DEATH; CELL PROLIFERATION; CELL SURFACE; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DRUG ACTIVITY; GROWTH RETARDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL CULTURE; CELL LINE; DRUG EFFECT; DRUG SCREENING; GENETICS; LIVER CELL; MELANOCYTE; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHONDROITIN SULFATE PROTEOGLYCANS; HEPATOCYTES; HUMANS; MALE; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; PROTEOME; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78549274417     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-301     Document Type: Article

References (34)

1. Balch C, Buzaid A, Soong S, Atkins M, Cascinelli N, Coit D, Fleming I, Gershenwald J, Houghton A, Kirkwood J, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001, 19:3635-3648.
2. Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance. Recent Results Cancer Res 2003, 161:93-110.
3. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance 1. Crit Rev Immunol 2004, 24:267-296. 10.1615/CritRevImmunol.v24.i4.40, 15588226.
4. Vergilis I, Szarek M, Ferrone S, Reynolds S. Presence and Prognostic Significance of Melanoma-Associated Antigens CYT-MAA and HMW-MAA in Serum of Patients with Melanoma. J Investig Dermatol 2005, 125:526-531. 10.1111/j.0022-202X.2005.23798.x, 16117794.
5. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, Lim L, Manser E, Furcht LT, Iida J. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999, 1:507-513. 10.1038/70302, 10587647.
6. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004, 165:881-891. 10.1083/jcb.200403174, 2172406, 15210734.
7. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 2009, 69:7538-7547. 10.1158/0008-5472.CAN-08-4626, 2762355, 19738072.
8. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, Tam E, Overall CM, McCarthy JB. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 2007, 403:553-563. 10.1042/BJ20061176, 1876388, 17217338.
9. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci 2004, 1028:340-350. 10.1196/annals.1322.040, 15650259.
10. Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kugler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dorrie J, et al. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res 2008, 18:73-84. 10.1097/CMR.0b013e3282f7c8f9, 2741307, 18337643.
11. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:466-470. 10.1073/pnas.89.2.466, 48259, 1731316.
12. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162. 10.1172/JCI6926, 408479, 10411544.
13. Soria J, Smit E, Khayat D, Besse B, Yang X, Hsu C, Reese D, Wiezorek J, Blackhall F. Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 2010, 9:1527-1533.
14. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2 1. Int J Cancer 2004, 109:281-290. 10.1002/ijc.11702, 14750182.
15. Bremer E, Samplonius D, Kroesen BJ, van Genne L, de Leij L, Helfrich W. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 2004, 6:636-645. 10.1593/neo.04229, 1531668, 15548373.
16. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, Helfrich W. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005, 280:10025-10033. 10.1074/jbc.M413673200, 15644326.
17. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005, 65:3380-3388.
18. Bremer E, de Bruyn M, Samplonius DF, Bijma T, Ten Cate B, de Leij LF, Helfrich W. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. J Mol Med 2008, 86:909-924. 10.1007/s00109-008-0348-9, 2491411, 18504532.
19. Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G, Helfrich W, Haisma H. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008, 16:1919-1926. 10.1038/mt.2008.203, 18813279.
20. Stieglmaier J, Bremer E, Kellner C, Liebig TM, Ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Buhring HJ, Greil J, et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein 274. Cancer Immunol Immunother 2008, 57:233-246. 10.1007/s00262-007-0370-8, 17665197.
21. Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J, Wajant H. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 2000, 275:32208-32213. 10.1074/jbc.M000482200, 10807904.
22. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152-3161. 10.1038/sj.onc.1206456, 12789291.
23. Brent PJ, Pang GT. [sigma] Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. European Journal of Pharmacology 1995, 278:151-160. 10.1016/0014-2999(95)00115-2, 7671999.
24. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004, 64:4875-4886. 10.1158/0008-5472.CAN-03-3180, 15256458.
25. Rybczynska AA, Dierckx RA, Ishiwata K, Elsinga PH, van Waarde A. Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation. J Nucl Med 2008, 49:2049-2056. 10.2967/jnumed.108.053876, 18997057.
26. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55:408-413.
27. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 2. J Invest Dermatol 2005, 125:1010-1019. 10.1111/j.0022-202X.2005.23900.x, 16297203.
28. Chien AJ, Moon RT. WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci 2007, 12:448-457. 10.2741/2074, 17127309.
29. O'Connell MP, Weeraratna AT. Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res 2009, 22:724-739. 10.1111/j.1755-148X.2009.00627.x, 19708915.
30. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL, Moon RT. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA 2009, 106:1193-1198. 10.1073/pnas.0811902106, 2626610, 19144919.
31. Chawla-Sarkar M, Bauer J, Lupica J, Morrison B, Tang Z, Oates R, Almasan A, DiDonato J, Borden E, Lindner D. Suppression of NF-+|B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL. Journal of Biological Chemistry 2003, 278:39461-39469. 10.1074/jbc.M306111200, 2080861, 12881518.
32. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic?. Hepatology 2001, 34:3-6. 10.1053/jhep.2001.25173a, 11431726.
33. Ivanov V, Zhou H, Partridge M, Hei T. Inhibition of Ataxia Telangiectasia Mutated Kinase Activity Enhances TRAIL-Mediated Apoptosis in Human Melanoma Cells. Cancer Res 2009, 69:3510-3519. 10.1158/0008-5472.CAN-08-3883, 19351839.
34. Yoshida T, Zhang Y, Rivera Rosado L, Zhang B. Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through Its Death Receptors in MDA-MB-231 Breast Cancer Cells. Molecular Cancer Research 2009, 7:1835-1844. 10.1158/1541-7786.MCR-09-0244, 19843632.